Skip to main content
Top
Published in: Endocrine 2/2020

01-08-2020 | Neurofibromatosis Type 1 | Original Article

Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1

Authors: Eleni Magdalini Kyritsi, Maria Hasiotou, Christina Kanaka-Gantenbein

Published in: Endocrine | Issue 2/2020

Login to get access

Abstract

Purpose

To describe the case of a 9-year-old male patient with neurofibromatosis type 1 (NF1), partial empty sella (PES), transient central adrenal insufficiency (CAI) and growth hormone (GH) deficiency (GHD) treated with recombinant GH (rGH).

Methods

The diagnosis of GHD was established upon peak GH response <10 ng/mL following glucagon and clonidine stimulation tests. CAI was diagnosed when peak cortisol response was <18 μg/dL following 1 μg Synacthen test (ST) with normal ACTH levels.

Results

The diagnosis of NF1 was made at the age of 1.5 year. The patient first attended our Department at the age of 4.5 years. He presented with short stature (height: 95 cm < 3rd percentile), macrocephaly, frontal bossing, café-au-lait spots and bilateral proptosis. His growth rate (GR) initially was 5.3 cm/year. Brain/pituitary MRI showed T2-hyperintensities typical for NF1 and PES with reduced pituitary gland height (3 mm). The pituitary function tests revealed GHD. During follow-up his imaging findings remained unchanged, while his GR decelerated. He was started on rGH at the age of 8.5 years. Within the following year he grew 8.7 cm in height and could preserve a normal GR thereafter. At the age of 10.3 years, he was diagnosed with CAI (maximum cortisol response post-1 μg ST: 13.1 μg/dL). Ηe received hydrocortisone for 1 year. A repeat 1 μg ST off hydrocortisone showed normal cortisol response. During follow-up, brain MRI findings remained stable, while his pituitary demonstrated normal size and signal intensity.

Conclusion

Empty sella and hypopituitarism may occur in the context of NF1. Short stature may be associated with GHD in the absence of intrasellar masses in affected individuals. Lifelong endocrine follow-up is recommended for all NF1 patients.
Literature
1.
go back to reference A.C. Hirbe, D.H. Gutmann, Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 13(8), 834–843 (2014)PubMed A.C. Hirbe, D.H. Gutmann, Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 13(8), 834–843 (2014)PubMed
2.
go back to reference V.C. Williams, J. Lucas, M.A. Babcock, D.H. Gutmann, B. Korf, B.L. Maria, Neurofibromatosis type 1 revisited. Pediatrics 123(1), 124–133 (2009)PubMed V.C. Williams, J. Lucas, M.A. Babcock, D.H. Gutmann, B. Korf, B.L. Maria, Neurofibromatosis type 1 revisited. Pediatrics 123(1), 124–133 (2009)PubMed
3.
go back to reference B. Hegedus, T.H. Yeh, D.Y. Lee, R.J. Emnett, J. Li, D.H. Gutmann, Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum. Mol. Genet. 17(19), 2956–2966 (2008)PubMedPubMedCentral B. Hegedus, T.H. Yeh, D.Y. Lee, R.J. Emnett, J. Li, D.H. Gutmann, Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum. Mol. Genet. 17(19), 2956–2966 (2008)PubMedPubMedCentral
4.
go back to reference Y.S. Yap, J.R. McPherson, C.K. Ong, S.G. Rozen, B.T. Teh, A.S. Lee, D.F. Callen, The NF1 gene revisited—from bench to bedside. Oncotarget 5(15), 5873–5892 (2014)PubMedPubMedCentral Y.S. Yap, J.R. McPherson, C.K. Ong, S.G. Rozen, B.T. Teh, A.S. Lee, D.F. Callen, The NF1 gene revisited—from bench to bedside. Oncotarget 5(15), 5873–5892 (2014)PubMedPubMedCentral
5.
go back to reference S. El-Watidy, A. Jamjoom, Z.A. Jamjoom, W. Selen, Cranio-orbital anomalies in Von Recklinghausen neurofibromatosis simulating an intraorbital space-occupying lesion. Ann. Saudi. Med. 15(4), 399–401 (1995)PubMed S. El-Watidy, A. Jamjoom, Z.A. Jamjoom, W. Selen, Cranio-orbital anomalies in Von Recklinghausen neurofibromatosis simulating an intraorbital space-occupying lesion. Ann. Saudi. Med. 15(4), 399–401 (1995)PubMed
6.
go back to reference E.A. Soucy, D. van Oppen, N.L. Nejedly, F. Gao, D.H. Gutmann, A.S. Hollander, Height assessments in children with neurofibromatosis type 1. J. Child. Neurol. 28(3), 303–307 (2013)PubMed E.A. Soucy, D. van Oppen, N.L. Nejedly, F. Gao, D.H. Gutmann, A.S. Hollander, Height assessments in children with neurofibromatosis type 1. J. Child. Neurol. 28(3), 303–307 (2013)PubMed
7.
go back to reference M. Clementi, S. Milani, I. Mammi, S. Boni, C. Monciotti, R. Tenconi, Neurofibromatosis type 1 growth charts. Am. J. Med. Genet. 87(4), 317–323 (1999)PubMed M. Clementi, S. Milani, I. Mammi, S. Boni, C. Monciotti, R. Tenconi, Neurofibromatosis type 1 growth charts. Am. J. Med. Genet. 87(4), 317–323 (1999)PubMed
8.
go back to reference J. Szudek, P. Birch, J.M. Friedman, Growth in North American white children with neurofibromatosis 1 (NF1). J. Med. Genet. 37(12), 933–938 (2000)PubMedPubMedCentral J. Szudek, P. Birch, J.M. Friedman, Growth in North American white children with neurofibromatosis 1 (NF1). J. Med. Genet. 37(12), 933–938 (2000)PubMedPubMedCentral
9.
go back to reference R. Vassilopoulou-Sellin, M.J. Klein, J.K. Slopis, Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr. Neurol. 22(5), 355–358 (2000)PubMed R. Vassilopoulou-Sellin, M.J. Klein, J.K. Slopis, Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr. Neurol. 22(5), 355–358 (2000)PubMed
10.
go back to reference S.J. Howell, P. Wilton, A. Lindberg, S.M. Shalet, Growth hormone replacement and the risk of malignancy in children with neurofibromatosis. J. Pediatr. 133(2), 201–205 (1998)PubMed S.J. Howell, P. Wilton, A. Lindberg, S.M. Shalet, Growth hormone replacement and the risk of malignancy in children with neurofibromatosis. J. Pediatr. 133(2), 201–205 (1998)PubMed
12.
go back to reference S. Raman, A. Grimberg, S.G. Waguespack, B.S. Miller, C.A. Sklar, L.R. Meacham, B.C. Patterson, Risk of neoplasia in pediatric patients receiving growth hormone therapy–a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J. Clin. Endocrinol. Metab. 100(6), 2192–2203 (2015)PubMedPubMedCentral S. Raman, A. Grimberg, S.G. Waguespack, B.S. Miller, C.A. Sklar, L.R. Meacham, B.C. Patterson, Risk of neoplasia in pediatric patients receiving growth hormone therapy–a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J. Clin. Endocrinol. Metab. 100(6), 2192–2203 (2015)PubMedPubMedCentral
13.
go back to reference C. Bizzarri, G. Bottaro, Endocrine implications of neurofibromatosis 1 in childhood. Horm. Res. Paediatr. 83(4), 232–241 (2015)PubMed C. Bizzarri, G. Bottaro, Endocrine implications of neurofibromatosis 1 in childhood. Horm. Res. Paediatr. 83(4), 232–241 (2015)PubMed
14.
go back to reference I. Sani, A. Albanese, Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm. Res. Paediatr. 87(3), 179–188 (2017)PubMed I. Sani, A. Albanese, Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm. Res. Paediatr. 87(3), 179–188 (2017)PubMed
15.
go back to reference D. Carmi, M. Shohat, A. Metzker, Z. Dickerman, Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 103(6 Pt 1), 1257–1262 (1999)PubMed D. Carmi, M. Shohat, A. Metzker, Z. Dickerman, Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 103(6 Pt 1), 1257–1262 (1999)PubMed
16.
go back to reference R. Virdis, M.E. Street, M.A. Bandello, C. Tripodi, A. Donadio, A.R. Villani, L. Cagozzi, L. Garavelli, S. Bernasconi, Growth and pubertal disorders in neurofibromatosis type 1. J. Pediatr. Endocrinol. Metab. 16(Suppl 2), 289–292 (2003)PubMed R. Virdis, M.E. Street, M.A. Bandello, C. Tripodi, A. Donadio, A.R. Villani, L. Cagozzi, L. Garavelli, S. Bernasconi, Growth and pubertal disorders in neurofibromatosis type 1. J. Pediatr. Endocrinol. Metab. 16(Suppl 2), 289–292 (2003)PubMed
17.
go back to reference M.L. Iezzi, G. Varriale, L. Zagaroli, M. Greco, S. Lasorella, A. Verrotti di Pianella, Growth hormone deficit as a first clinical manifestation of early diffuse cerebral glioma in patient with neurofibromatosis. Ann. Clin. Lab. Res. 5, 1 (2017) M.L. Iezzi, G. Varriale, L. Zagaroli, M. Greco, S. Lasorella, A. Verrotti di Pianella, Growth hormone deficit as a first clinical manifestation of early diffuse cerebral glioma in patient with neurofibromatosis. Ann. Clin. Lab. Res. 5, 1 (2017)
18.
go back to reference M.H. Cnossen, E.N. Stam, L.C. Cooiman, H.J. Simonsz, H. Stroink, A.P. Oranje, D.J. Halley, A. de Goede-Bolder, M.F. Niermeijer, S.M.de Muinck Keizer-Schrama, Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100(4), 667–670 (1997).PubMed M.H. Cnossen, E.N. Stam, L.C. Cooiman, H.J. Simonsz, H. Stroink, A.P. Oranje, D.J. Halley, A. de Goede-Bolder, M.F. Niermeijer, S.M.de Muinck Keizer-Schrama, Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100(4), 667–670 (1997).PubMed
19.
go back to reference A.R. Shepard, W. Zhang, N.L. Eberhardt, Two CGTCA motifs and a GHF1/Pit1 binding site mediate cAMP-dependent protein kinase a regulation of human growth hormone gene expression in rat anterior pituitary GC cells. J. Biol. Chem. 269(3), 1804–1814 (1994)PubMed A.R. Shepard, W. Zhang, N.L. Eberhardt, Two CGTCA motifs and a GHF1/Pit1 binding site mediate cAMP-dependent protein kinase a regulation of human growth hormone gene expression in rat anterior pituitary GC cells. J. Biol. Chem. 269(3), 1804–1814 (1994)PubMed
20.
go back to reference B. Dasgupta, L.L. Dugan, D.H. Gutmann, The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 23(26), 8949–8954 (2003)PubMedPubMedCentral B. Dasgupta, L.L. Dugan, D.H. Gutmann, The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 23(26), 8949–8954 (2003)PubMedPubMedCentral
21.
go back to reference E.H. Burrows, Bone changes in orbital neurofibromatosis. Br. J. Radiol. 36, 549–561 (1963)PubMed E.H. Burrows, Bone changes in orbital neurofibromatosis. Br. J. Radiol. 36, 549–561 (1963)PubMed
22.
go back to reference S.K. Gupta, H.V. Nema, P.L. Bhatia, K. Sasibabu, R. Kesharwani, The radiological features of craniofacial neurofibromatosis. Clin. Radiol. 30(5), 553–557 (1979)PubMed S.K. Gupta, H.V. Nema, P.L. Bhatia, K. Sasibabu, R. Kesharwani, The radiological features of craniofacial neurofibromatosis. Clin. Radiol. 30(5), 553–557 (1979)PubMed
23.
go back to reference R.L. Agrawal, S. Bhargava, A.H. Samma, A.K. Kothari, H.K. Bedi, R.L. Shrimali, Empty sella syndrome with neurofibromatosis. Indian J. Ophthalmol. 24(4), 38–40 (1977)PubMed R.L. Agrawal, S. Bhargava, A.H. Samma, A.K. Kothari, H.K. Bedi, R.L. Shrimali, Empty sella syndrome with neurofibromatosis. Indian J. Ophthalmol. 24(4), 38–40 (1977)PubMed
24.
go back to reference D. Miljic, S. Pekic, V. Popovic, Empty sella. In Endotext [Internet], eds by K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J.E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D.L. Trence, A. Vinik, D.P. Wilson (MDText.com, Inc, South Dartmouth, MA, 2018) D. Miljic, S. Pekic, V. Popovic, Empty sella. In Endotext [Internet], eds by K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J.E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D.L. Trence, A. Vinik, D.P. Wilson (MDText.com, Inc, South Dartmouth, MA, 2018)
25.
go back to reference L. De Marinis, S. Bonadonna, A. Bianchi, G. Maira, A. Giustina, Primary empty sella. J. Clin. Endocrinol. Metab. 90(9), 5471–5477 (2005)PubMed L. De Marinis, S. Bonadonna, A. Bianchi, G. Maira, A. Giustina, Primary empty sella. J. Clin. Endocrinol. Metab. 90(9), 5471–5477 (2005)PubMed
26.
go back to reference S. Chiloiro, A. Giampietro, A. Bianchi, T. Tartaglione, A. Capobianco, C. Anile, L. De Marinis, Diagnosis of endocrine disease: primary empty sella: a comprehensive review. Eur. J. Endocrinol. 177(6), R275–R285 (2017)PubMed S. Chiloiro, A. Giampietro, A. Bianchi, T. Tartaglione, A. Capobianco, C. Anile, L. De Marinis, Diagnosis of endocrine disease: primary empty sella: a comprehensive review. Eur. J. Endocrinol. 177(6), R275–R285 (2017)PubMed
27.
go back to reference A.M. Lenz, A.W. Root, Empty sella syndrome. Pediatr. Endocrinol. Rev. 9(4), 710–715 (2012)PubMed A.M. Lenz, A.W. Root, Empty sella syndrome. Pediatr. Endocrinol. Rev. 9(4), 710–715 (2012)PubMed
28.
go back to reference D. Rath, R.K. Sahoo, J. Choudhury, D.K. Dash, A. Mohapatra, Empty sella syndrome in a male child with failure to thrive. J. Pediatr. Neurosci. 10(1), 45–47 (2015)PubMedPubMedCentral D. Rath, R.K. Sahoo, J. Choudhury, D.K. Dash, A. Mohapatra, Empty sella syndrome in a male child with failure to thrive. J. Pediatr. Neurosci. 10(1), 45–47 (2015)PubMedPubMedCentral
29.
go back to reference R.E. Ferner, D.H. Gutmann, Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939–955 (2013)PubMed R.E. Ferner, D.H. Gutmann, Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939–955 (2013)PubMed
30.
go back to reference P. Julayanont, A. Karukote, D. Ruthirago, D. Panikkath, R. Panikkath, Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects. J. Pain. Res. 9, 87–99 (2016)PubMedPubMedCentral P. Julayanont, A. Karukote, D. Ruthirago, D. Panikkath, R. Panikkath, Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects. J. Pain. Res. 9, 87–99 (2016)PubMedPubMedCentral
31.
go back to reference A.L. Gilbert, G. Heidary, Update on the evaluation of pediatric idiopathic intracranial hypertension. Curr. Opin. Ophthalmol. 27(6), 493–497 (2016)PubMed A.L. Gilbert, G. Heidary, Update on the evaluation of pediatric idiopathic intracranial hypertension. Curr. Opin. Ophthalmol. 27(6), 493–497 (2016)PubMed
32.
go back to reference B. Shofty, L. Ben-Sira, S. Constantini, S. Freedman, A. Kesler, Optic nerve sheath diameter on MR imaging: establishment of norms and comparison of pediatric patients with idiopathic intracranial hypertension with healthy controls. AJNR Am. J. Neuroradiol. 33(2), 366–369 (2012)PubMed B. Shofty, L. Ben-Sira, S. Constantini, S. Freedman, A. Kesler, Optic nerve sheath diameter on MR imaging: establishment of norms and comparison of pediatric patients with idiopathic intracranial hypertension with healthy controls. AJNR Am. J. Neuroradiol. 33(2), 366–369 (2012)PubMed
33.
go back to reference T. Mushtaq, F. Shakur, J.K. Wales, N.P. Wright, Reliability of the low dose synacthen test in children undergoing pituitary function testing. J. Pediatr. Endocrinol. Metab. 21(12), 1129–1132 (2008)PubMed T. Mushtaq, F. Shakur, J.K. Wales, N.P. Wright, Reliability of the low dose synacthen test in children undergoing pituitary function testing. J. Pediatr. Endocrinol. Metab. 21(12), 1129–1132 (2008)PubMed
34.
go back to reference M.C. Raux Demay, J.P. Magny, N. Idrès, A. Grimfeld, Y. Le Bouc, Use of the low-dose corticotropin stimulation test for the monitoring of children with asthma treated with inhaled corticosteroids. Horm. Res. 66(2), 51–60 (2006)PubMed M.C. Raux Demay, J.P. Magny, N. Idrès, A. Grimfeld, Y. Le Bouc, Use of the low-dose corticotropin stimulation test for the monitoring of children with asthma treated with inhaled corticosteroids. Horm. Res. 66(2), 51–60 (2006)PubMed
35.
go back to reference L.M. Mongioì, R.A. Condorelli, F. Barbagallo, R. Cannarella, S. La Vignera, A.E. Calogero, Accuracy of the low-dose ACTH stimulation test for adrenal insufficiency diagnosis: a re-assessment of the cut-off value. J. Clin. Med. 8(6), pii: E806 (2019) L.M. Mongioì, R.A. Condorelli, F. Barbagallo, R. Cannarella, S. La Vignera, A.E. Calogero, Accuracy of the low-dose ACTH stimulation test for adrenal insufficiency diagnosis: a re-assessment of the cut-off value. J. Clin. Med. 8(6), pii: E806 (2019)
36.
go back to reference M. Wade, S. Baid, K. Calis, H. Raff, N. Sinaii, L. Nieman, Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test. Eur. J. Endocrinol. 162(1), 109–113 (2010)PubMed M. Wade, S. Baid, K. Calis, H. Raff, N. Sinaii, L. Nieman, Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test. Eur. J. Endocrinol. 162(1), 109–113 (2010)PubMed
37.
go back to reference A. Ciresi, S. Radellini, E. Vigneri, V. Guarnotta, J. Bianco, M.G. Mineo, C. Giordano, Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency. J. Endocrinol. Invest. 41(3), 333–342 (2018)PubMed A. Ciresi, S. Radellini, E. Vigneri, V. Guarnotta, J. Bianco, M.G. Mineo, C. Giordano, Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency. J. Endocrinol. Invest. 41(3), 333–342 (2018)PubMed
38.
go back to reference C. Giavoli, R. Libé, S. Corbetta, E. Ferrante, A. Lania, M. Arosio, A. Spada, P. Beck-Peccoz, Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 89(11), 5397–5401 (2004)PubMed C. Giavoli, R. Libé, S. Corbetta, E. Ferrante, A. Lania, M. Arosio, A. Spada, P. Beck-Peccoz, Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 89(11), 5397–5401 (2004)PubMed
39.
go back to reference C. Giavoli, Unmasking other pituitary deficits during growth hormone replacement therapy. Ann. Endocrinol. 68(4), 237–240 (2007) C. Giavoli, Unmasking other pituitary deficits during growth hormone replacement therapy. Ann. Endocrinol. 68(4), 237–240 (2007)
40.
go back to reference M. Tschöp, H. Lahner, H. Feldmeier, H. Grasberger, K.M. Morrison, O.E. Janssen, A.F. Attanasio, C.J. Strasburger, Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults. Eur. J. Endocrinol. 143(6), 769–773 (2000)PubMed M. Tschöp, H. Lahner, H. Feldmeier, H. Grasberger, K.M. Morrison, O.E. Janssen, A.F. Attanasio, C.J. Strasburger, Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults. Eur. J. Endocrinol. 143(6), 769–773 (2000)PubMed
41.
go back to reference L. De Paepe, R. Abs, J. Verlooy, A. Clemens, R.M. Smets, P. Louis, J.J. Martin, Benign intracranial hypertension as a cause of transient partial pituitary deficiency. J. Neurol. Sci. 114(2), 152–155 (1993)PubMed L. De Paepe, R. Abs, J. Verlooy, A. Clemens, R.M. Smets, P. Louis, J.J. Martin, Benign intracranial hypertension as a cause of transient partial pituitary deficiency. J. Neurol. Sci. 114(2), 152–155 (1993)PubMed
42.
go back to reference M.T. Zagardo, W.S. Cail, S.E. Kelman, M.I. Rothman, Reversible empty sella in idiopathic intracranial hypertension: an indicator of successful therapy? AJNR Am. J. Neuroradiol. 17(10), 1953–1956 (1996)PubMed M.T. Zagardo, W.S. Cail, S.E. Kelman, M.I. Rothman, Reversible empty sella in idiopathic intracranial hypertension: an indicator of successful therapy? AJNR Am. J. Neuroradiol. 17(10), 1953–1956 (1996)PubMed
43.
go back to reference V. Triggiani, V.A. Giagulli, M. Moschetta, E. Guastamacchia, An unusual case of reversible empty sella. Endocr. Metab. Immune Disord. Drug Targets. 16(2), 154–156 (2016)PubMed V. Triggiani, V.A. Giagulli, M. Moschetta, E. Guastamacchia, An unusual case of reversible empty sella. Endocr. Metab. Immune Disord. Drug Targets. 16(2), 154–156 (2016)PubMed
44.
go back to reference A. Giustina, G. Aimaretti, M. Bondanelli, F. Buzi, S. Cannavò, S. Cirillo, A. Colao, L. De Marinis, D. Ferone, M. Gasperi, S. Grottoli, T. Porcelli, E. Ghigo, E. degli Uberti, Primary empty sella: why and when to investigate hypothalamic-pituitary function. J. Endocrinol. Invest. 33(5), 343–346 (2010)PubMed A. Giustina, G. Aimaretti, M. Bondanelli, F. Buzi, S. Cannavò, S. Cirillo, A. Colao, L. De Marinis, D. Ferone, M. Gasperi, S. Grottoli, T. Porcelli, E. Ghigo, E. degli Uberti, Primary empty sella: why and when to investigate hypothalamic-pituitary function. J. Endocrinol. Invest. 33(5), 343–346 (2010)PubMed
45.
go back to reference R.E. Ferner, S.M. Huson, N. Thomas, C. Moss, H. Willshaw, D.G. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger, A. Kirby, Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44(2), 81–88 (2007)PubMed R.E. Ferner, S.M. Huson, N. Thomas, C. Moss, H. Willshaw, D.G. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger, A. Kirby, Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44(2), 81–88 (2007)PubMed
46.
go back to reference K.S. Cunha, E.P. Barboza, E.C. Fonseca, Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics 63(1), 39–42 (2008)PubMedPubMedCentral K.S. Cunha, E.P. Barboza, E.C. Fonseca, Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics 63(1), 39–42 (2008)PubMedPubMedCentral
47.
go back to reference U. Dagalakis, M. Lodish, E. Dombi, N. Sinaii, J. Sabo, A. Baldwin, S.M. Steinberg, C.A. Stratakis, B.C. Widemann, Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J. Pediatr. 164(3), 620–624 (2014)PubMed U. Dagalakis, M. Lodish, E. Dombi, N. Sinaii, J. Sabo, A. Baldwin, S.M. Steinberg, C.A. Stratakis, B.C. Widemann, Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J. Pediatr. 164(3), 620–624 (2014)PubMed
Metadata
Title
Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1
Authors
Eleni Magdalini Kyritsi
Maria Hasiotou
Christina Kanaka-Gantenbein
Publication date
01-08-2020
Publisher
Springer US
Published in
Endocrine / Issue 2/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02351-z

Other articles of this Issue 2/2020

Endocrine 2/2020 Go to the issue